



WORLD ECONOMIC FORUM



Technology
Pioneer
2007

NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX LIFE SCIENCES' TEST DETECTS SCRAPIE PRIONS IN BLOOD OF SCRAPIE-INFECTED SHEEP

TORONTO, Ontario – October 25, 2007 – Amorfix Life Sciences (TSX: AMF), a company focused on diagnostics and treatments for brain-wasting diseases, today announced the results from the testing of a blinded panel of blood samples from scrapie infected sheep. Amorfix correctly identified 18 out of 20 individual sheep blood samples in a blinded panel provided by an independent third-party laboratory, the Caine Veterinary Teaching Center, University of Idaho.

“These initial results demonstrate the ability of our diagnostic technology to identify endogenous prions which is important for the commercialization of our variant Creutzfeldt-Jacob Disease (vCJD) diagnostic blood test,” said Dr. George Adams, CEO of Amorfix Life Sciences. “These data plus additional results that we will generate will be included in the regulatory submission of a self-declared CE mark for the commercialization of the EP-vCJD™ test. Moreover, while the EP-vCJD™ test is our lead diagnostic candidate, these results present a new commercial opportunity for the testing of all sheep and selective removal of infected animals.”

Dr. Marni Uger, Associate Director, Research and Development of Amorfix, will be presenting these data at the European Commission workshop on vCJD diagnostic assays in Brussels, Belgium tomorrow. Amorfix correctly scored 11 out of 12 positive samples and 7 out of 8 negative samples. It is unknown if all sheep with scrapie have endogenous prions in their blood. At present there is no effective blood diagnostic test that can identify scrapie prions in sheep. Amorfix had previously reported the adaptation of its EP-vCJD™ assay to detect sheep scrapie brain prions spiked into sheep plasma. The ability to identify endogenous scrapie prions in the blood of sheep is a key milestone in the development of Amorfix's EP-vCJD™ diagnostic test.

Scrapie is a brain wasting disease found in sheep analogous to mad cow disease in cattle and vCJD in humans.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jacob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3813 Fax: (416) 482-3811 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3814 Fax: (416) 482-3811 james.parsons@amorfix.com
---	--